-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MK-0616 in Hypercholesterolemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.MK-0616 in Hypercholesterolemia Drug Details:MK-0616 is under development for the treatment of atherosclerotic cardiovascular disease (ASCVD)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MIV-711 in Osteoarthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MIV-711 in OsteoarthritisDrug Details:MIV-711 is under development for the treatment of osteoarthritis. The drug candidate is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Fostroxacitabine Bralpamide Hydrochloride in Hepatocellular Carcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Fostroxacitabine Bralpamide Hydrochloride in Hepatocellular CarcinomaDrug Details:fostroxacitabine bralpamide (MIV-818) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Inavolisib in Metastatic Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Inavolisib in Metastatic Breast Cancer Drug Details: Inavolisib (GDC-0077) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Fimavacc in Head And Neck Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Fimavacc in Head And Neck Cancer Drug Details:Fimavacc is under development for the treatment of melanoma and...
-
Product Insights
Bile Duct Cancer (Cholangiocarcinoma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bile Duct Cancer Pipeline Drugs Market Report Overview Bile duct cancer (cholangiocarcinoma) are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers), and weight loss. Treatment includes chemotherapy and radiation therapy. The Bile Duct Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Bile Duct Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of...
-
Product Insights
![]()
Net Present Value Model: Fostroxacitabine bralpamide
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Fostroxacitabine bralpamide Drug Details fostroxacitabine bralpamide...
-
Track & Monitor
![]()
Innovation in Pharmaceuticals: Nucleoside chemical synthesis
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – fostroxacitabine bralpamide hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry fostroxacitabine bralpamide hydrochloride Drug Details fostroxacitabine bralpamide (MIV-818) is under development for the treatment...
-
Product Insights
Bladder Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Bladder cancer occurs in tissues of the urinary bladder whose symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body, and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, and certain parasitic infections. The Bladder Cancer pipeline market research report provides comprehensive...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – MIV-711
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MIV-711 Drug Details MIV-711 is under development for the treatment of osteoarthritis. The drug...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Product Insights
Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. The Histone Deacetylase 3 pipeline drugs market research report outlays comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Histone Deacetylase 3 (SMAP45...
-
Sector Analysis
Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Histone Deacetylase 2 pipeline drugs market research report outlays comprehensive information on the Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Gastrointestinal, Immunology, Infectious Disease, and Musculoskeletal Disorders, which include indications.
-
Product Insights
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Histone Deacetylase 6 (HDAC6) gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression, and developmental events. It also plays a central role in microtubule-dependent cell motility via the deacetylation of tubulin. The HDAC6 pipeline market research report provides comprehensive information on the HDAC6 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Histone Deacetylase 1 pipeline drugs market research report outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type, that are being developed by companies/universities. The report also covers products from therapy areas such as Oncology, Central Nervous System, Genetic Disorders, Hematological Disorders, Cardiovascular, Gastrointestinal, Immunology, Infectious Disease, and Musculoskeletal Disorders, which include indications.
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. The basal cell carcinoma pipeline drugs market research report provides an analysis of the basal cell carcinoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers...
-
Product Insights
Hepatitis C Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Hepatitis C occurs with multiple symptoms including abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea, and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant, and blood transfusion. The Hepatitis C pipeline drugs market research report provides an analysis of the Hepatitis C drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Osteoarthritis pipeline market research report provides comprehensive information on the therapeutics under development for Osteoarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects.
-
Product Insights
Herpes Labialis (Oral Herpes) – Global Clinical Trials Review, H2, 2021
GlobalData's clinical trial report, “Herpes Labialis (Oral Herpes) - Global Clinical Trials Review, H2, 2021" provides an overview of Herpes Labialis (Oral Herpes) Clinical trials scenario. This report provides top line data relating to the clinical trials on Herpes Labialis (Oral Herpes) . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.